|
|
|
|
Research Article
|
|
Anticonvulsant, Anxiolytic and Hypnotic effects of Aqueous Bulb Extract of Crinum glaucum A. Chev (Amaryllidaceae): Role of GABAergic and Nitrergic Systems |
|
Ismail O. Ishola,
Sunday O. Olayemi
and
Abidemi R. Idowu
|
|
|
ABSTRACT
|
Crinum glaucum A. Chev (Amaryllidaceae) (CG) is a bulbous plant widely used in folk medicine in the treatment of cough, asthma and convulsions. This study was carried out to investigate the anticonvulsant, anxiolytic and hypnotic effects of the aqueous bulb extract of C. glaucum and its possible mechanism (s) of action. The anticonvulsant activity of C. glaucum extract (400-1200 mg kg-1 p.o.) was investigated using picrotoxin, strychnine, isoniazid, pentylenetetrazol and N-methyl-D-aspartate (NMDA)-induced seizures in mice while the elevated plus maze test (EPM) and hexobarbitone-induced sleeping time (HIST) were used to evaluate the anxiolytic and hypnotic effects, respectively. Animals were pretreated with flumazenil (3 mg kg-1; i.p. GABAA receptor antagonist), cyproheptadine (4 mg kg-1; i.p. 5-HT2 receptor antagonist), L-arginine (500 mg kg-1; p.o. Nitric Oxide (NO) precursor) and L-Nitroarginine (L-NNA) (10 mg kg-1 i.p. Nitric Oxide Synthase (NOS) inhibitor) were used to investigate the probable mechanism (s) of anticonvulsant activity. Oral administration of CG significantly (p<0.001) delayed the onset of seizures induced by picrotoxin, strychnine, isoniazid and pentylenetetrazol with peak effect at 1200 mg kg-1 in comparison to control groups. CG (800 and 1200 mg kg-1) strongly antagonized NMDA-induced turning behavior. Pretreatment of mice with cyproheptadine could not reverse the anticonvulsant effect of CG. However, pretreatment with flumazenil and L-NNA significantly (p<0.05) reversed the anticonvulsant effect of CG while L-arginine pretreatment significantly (p<0.001) delayed the onset of seizures when compared with control and extract (1200 mg kg-1 only). CG potentiated hexobarbitone-induced sleeping time with peak effect at 400 mg kg-1 and also significantly (p<0.05) increased open arm exploration in EPM and had its peak anxiolytic effect at 100 mg kg-1. The data obtained suggests that aqueous bulb extract of Crinum glaucum possess anticonvulsant, anxiolytic and hypnotic activities which involve an interaction with GABAergic, nitrergic and glutaminergic systems to exert its effects.
|
|
|
|
How
to cite this article:
Ismail O. Ishola, Sunday O. Olayemi and Abidemi R. Idowu, 2013. Anticonvulsant, Anxiolytic and Hypnotic effects of Aqueous Bulb Extract of Crinum glaucum A. Chev (Amaryllidaceae): Role of GABAergic and Nitrergic Systems. Pakistan Journal of Biological Sciences, 16: 701-710. DOI: 10.3923/pjbs.2013.701.710 URL: https://scialert.net/abstract/?doi=pjbs.2013.701.710
|
|
|
Received: December 07, 2012;
Accepted: February 19, 2013;
Published: April 04, 2013
|
|
INTRODUCTION
Crinum glaucum A.Chev (Amaryllidaceae) is a bulbous plant widely used
in folk medicine in West Africa. The common English names are river lily, String-lily,
swamp-lily, Crinum lily and Spider lily. In Zulu tribe its known as umNduze.
In Nigeria, its known as Isumeri (Gbile,
1984) in the Yoruba speaking regions, Ede chukwu or Ede
mmo (Gods Cocoyam) in Igbo speaking regions and Albasar kwaadi
(Frogs onion) in Hausa speaking regions. The bulbs of Crinum glaucum
is used in Southwestern Nigeria as an effective remedy in the relief of cough,
asthma and convulsions by traditional medicine practitioners (Burkill,
1985; Okpo and Adeyemi, 2002). They are also used
as anti-helminthic and emetics (Oliver, 1959) and in
the treatment of sores (Kokwako, 1976), sexually transmitted
diseases and backache (Duri et al., 1994). It
is cut into small pieces and soaked in water for three days; the liquid (aqueous
extract) is then decanted and drank to cure these ailments. The bulb is also
used in Southern Nigeria for memory loss and other mental symptoms associated
with ageing (Houghton et al., 2004). The aqueous
extract is widely used in folk medicine in West Africa as an antispasmodic.
Studies have shown a non-specific relaxant effect of Crinum glaucum on
gastrointestinal smooth muscles (Okpo and Adeyemi, 1998),
analgesic and anti-inflammatory effects (Okpo et al.,
2001) and antiallergic effect (Okpo and Adeyemi, 2002).
Based on literature search, no study has been carried out to scientifically
validate the folkloric uses of Crinum glaucum in the treatment of convulsive
and anxiety disorders. Hence, this study was carried out to investigate the
anticonvulsant, anxiolytic and hypnotic effects of the aqueous bulb extract
of Crinum glaucum in mice and its probable mechanism(s) of action.
MATERIAL AND METHODS
Plant material: Fresh bulbs of Crinum glaucum were purchased
from herb sellers in Mushin market, Mushin, Lagos, Nigeria and botanical authentication
was carried out by Mr. T.K. Odewo of the Herbarium in the Department of Botany,
Faculty of Science, University of Lagos, Akoka, Nigeria, where the herbarium
voucher was deposited with the voucher specimen number LUH 5082.
Drugs: Pentylenetetrazol (PTZ), picrotoxin, L-arginine, L-NG-Nitroarginine,
strychnine, N-methyl-D-aspartic acid (NMDA), hexobarbitone and cyproheptadine
(Sigma Aldrich, St. Louis, MO, USA), phenobarbitone (May and Baker, Lagos, Nigeria),
flumazenil (Hikma Farmaceutical, Portugal, S.A.), diazepam (Swipha pharmaceuticals,
Nigeria), isoniazid (Mancleods Pharmaceuticals Ltd., India) and normal saline
(Unique pharmaceutical limited, Lagos, Nigeria).
Animals: Experimental animals Albino mice of both sexes weighing between
20-25 g were obtained and kept at the Laboratory Animal Centre of the College
of Medicine, University of Lagos. The animals maintained under standard environmental
conditions had free access to standard diet (Pfizer Feeds, PLC, Lagos, Nigeria)
and water ad libitum. The experimental procedures were carried out in
accordance with the United States National Institute of Health Guidelines for
Care and Use of Laboratory Animals in Biomedical Research (NIH,
1985).
Preparation of plant extract: The fresh bulbs of Crinum glaucum (1.78
kg) were cut into small pieces and soaked in 5 L of distilled water. On day
4, the liquid was decanted and filtered. The filtrate was evaporated to dryness
in an oven set at 40°C. A dark brown sticky extract was obtained and stored
in airtight bottles in a refrigerator until they were ready for use. The dried
extract obtained was weighed. The percentage yield was 3.26%.
Acute toxicity testing: Toxicity of plant extract was determined using
the method described by Adeyemi et al. (2007).
Mice were fasted for 12 h, divided into five groups: Group I-IV were given CG
(1, 2, 4 and 8 g kg-1; p.o) and Group V-normal saline (10 mL kg-1;
p.o). Mice were observed for behavioral changes and toxic symptoms for the first
2 h after administration and mortality for a period of 14 days.
Anticonvulsant test
Picrotoxin-or isoniazid-induced convulsions: For each chemoconvulsant 60
mice were used (n = 10). Normal saline (10 mL kg-1, p.o) was given
to control group, phenobarbitone (40 mg kg-1, i.p.) was given as
a reference standard and CG (200-1200 mg kg-1, p.o.). Thirty minutes
(i.p.) or 1 h (p.o.) after treatment, the mice were given picrotoxin (7 mg kg-1,
i.p.) or Isoniazid (250 mg kg-1, i.p., seizure consisted of clonic
tonic convulsion and wild running around and death). The presence or absence
of clonic convulsions was noted for 60 min following administration of convulsants
and percentage protections were recorded (Perazzo et
al., 2003; Bernasconi et al., 1988).
Strychnine-pentylenetetrazol-induced seizures: For each chemoconvulsant
35 mice were used (n = 7). Normal saline (10 mL kg-1, p.o) was given
to control group, phenobarbitone (40 mg kg-1, i.p.) was given as
a reference standard and CG (400-1200 mg kg-1, p.o.). Thirty minutes
(i.p.) or 1 h (p.o.) after treatment, the mice were given strychnine (5 mg kg-1,
i.p.) or pentylenetetrazol (90 mg kg-1, i.p.). The latency to convulsion
and percentage protection were recorded (Adeyemi et
al., 2007; Gupta et al., 2012).
NMDA induced seizures in mice: Thirty five mice of either sex were randomly
allotted to 5 groups (n = 7). Treatment was carried out as follows: Group 1:
Normal Saline (NS) (10 mL kg-1 p.o.), Group 2: Phenobarbitone (40
mg kg-1 i.p.) and Group 3-5: CG (400, 800 and 1200 mg kg-1,
p.o.). Mice were injected (i.p) with NMDA, 100 mg kg-1, 1 h after
intraperitoneal or oral administration of the extract and were observed for
30 min. Turning behaviour was characterized by two consecutive 360° cycles
fulfilled by the same animal (Velisek, 2006). Animals
that did not exhibit turning behaviour within the 30 min observation period
were declared protected. The time of onset of this behaviour in non-protected
animals were recorded.
GABAergic pathway involvement: Fourty albino mice of either sex were
randomly allotted to 4 groups (n = 10). They were pretreated with flumazenil
(3 mg kg-1, i.p.). 15 min after pretreatment, Group I-Mice were given
normal saline (10 mL kg-1, p.o.)., Group II-Phenobarbitone (40 mg
kg-1, i.p.)., Group III and IV-CG (800 and 1200 mg kg-1).
Thirty minutes (i.p.) or 1 hour (p.o.) after treatment, the mice were given
picrotoxin (7 mg kg-1, i.p.). The latency to convulsion and percentage
protection were recorded (Nogueira and Vassilieff, 2000).
Serotonergic pathway involvement: Thirty albino mice of either sex were
randomly allotted to 3 groups (n = 10). They were pretreated with cyproheptadine
(4 mg kg-1, p.o). 15 minutes after pretreatment, Group I-Mice were
given normal saline (10 mL kg-1, p.o.)., Group II-Phenobarbitone
(40 mg kg-1, i.p.)., Group III-CG (1200 mg kg-1). Thirty
minutes (i.p.) or 1 hour (p.o.) after treatment, the mice were given picrotoxin
(7 mg kg-1, i.p.). The latency to convulsion and percentage protection
were recorded (Michael, 2006).
Nitric oxide pathway involvement: Fourty albino mice of either sex were
randomly allotted to 4 groups (n = 10). They were pretreated with nitric oxide
synthase inhibitor-L-NNA (10 mg kg-1, p.o) 15 minutes after pretreatment,
the animals were given normal saline or CG 1200 mg kg-1. The effect
of CG on nitric oxide synthesis was investigated through oral pretreatment with
L-arginine (500 mg kg-1, p.o.). 15 minutes after pretreatment, mice
were given normal saline (10 mL kg-1, p.o.) or CG (1200 mg kg-1).
1 hour (p.o.) after treatments, the mice were given picrotoxin (7 mg kg-1,
i.p.). The latency to convulsion and percentage protection were recorded (Paul
and Subramanian, 2002).
Hexobarbitone sleeping time: Five groups of 7 mice each were given normal
saline (10 mL kg-1, p.o.), CG (200, 800 and 1600 mg kg-1,
p.o.) and diazepam (3 mg kg-1, p.o.) respectively. One hour later,
hexobarbitone (100 mg kg-1, i.p.) was administered to each mouse
in turn. The mice were placed on their backs in separate chambers and the duration
of loss of righting reflex starting at the time of hexobarbitone administration
until they regained their righting reflexes were recorded. When there was any
doubt, the animal was placed gently on its back again and if it righted itself
within 1 min, this was regarded as the end point (Vogel and
Vogel, 1997; Mujumdar et al., 2000).
Elevated plus maze test: The EPM testing procedure was as described
by Pellow et al. (1985). The equipment was made
of wood and had four arms of equal dimensions (50x12 cm). Two of the arms were
enclosed by 40 cm high walls and were arranged perpendicularly to two opposite
open arms. The apparatus was elevated 50 cm above the floor. One hour following
oral administration of CG (200, 800 and 1600 mg kg-1, p.o.), diazepam
(1.5 mg kg-1, p.o.) and normal saline (10 mL kg-1, p.o.),
mice were placed in the centre of the maze facing an open arm. The cumulative
time spent in the open or closed arm were recorded for 5 min. The maze was cleaned
with an alcohol solution after each trial.
Statistical analysis: Results are expressed as Mean±S.E.M., statistical
analysis of data was done by a means of One-Way analysis of variance (ANOVA)
followed by Tukeys multiple
comparison tests. A level of significance (p<0.05, 0.01 or 0.001) was considered
for each test.
RESULTS
Acute toxicity study: Oral administration of the extract (1, 2, 4 and
8 g kg-1) caused 20, 40, 100 and 100% death of animals respectively.
These percentage responses were converted to probit values which were plotted
against log doses of the aqueous extract. The LD50 obtained (after
extrapolation) was 1.479 g kg-1. The aqueous extract was found to
cause behavioural toxic effects which include; calmness, hypoactivity, abdominal
writhing and stooling.
Anticonvulsant activity
Picrotoxin induced seizures: Picrotoxin (7 mg kg-1 i.p.) elicited
seizures in all the seven mice used in normal saline control group with an onset
of 240.00 ± 26.83 s and 100% mortality. Aqueous bulb extract of Crinum
glaucum (400 and 1200 mg kg-1) significantly (p<0.05; p<0.01)
delayed the onset of picrotoxin elicited clonic convulsion (468.00±81.39
and 528.00±81.39 s respectively) and 40% protection in comparison to
normal saline treated group in a dose dependent manner. Phenobarbitone (40 mg
kg-1) significantly (p<0.01) delayed the onset of seizures (542.20±50.91
s) with 100% protection (Table 1).
Isoniazid induced seizures: Isoniazid (250 mg kg-1 i.p.)
elicited clonic tonic convulsion in all the animals used. The normal saline
control group produced convulsion and showed an onset of 32.80±2.55 min.
The aqueous extract of C. glaucum (400-1200 mg kg-1) significantly
(p<0.01; 0.001) delayed the onset of isoniazid induced seizures from 32.80±2.55
min in control to 43.20±0.83, 40.60±0.55 and 53.00±0.97
min respectively and shows dose-dependent increase in the anticonvulsant activity.
Similarly, phenobarbitone 40 mg kg-1 pretreatment significantly (p<
0.001) increased the time to the onset of isoniazid induced seizures from 32.80±2.55
min to 47.00±2.10 min (Table 1).
Strychnine induced seizures: Strychnine (5 mg kg-1) produced
tonic convulsion in 100% of the mice used. CG (400, 800 and 1200 mg kg-1)
pretreatment significantly (p<0.05, 0.01, 0.001) increase the time of onset
of tonic seizure from 29.20±0.40 sec in normal saline treated control
to 67.60±8.69, 78.20±3.54 and 107.40±8.38 s, respectively
(Table 2).
Table 1: |
Effect of aqueous bulb extract of Crinum glaucum (CG)
in picrotoxin (PCT) and isoniazid (INH)-induced seizures in mice |
 |
The data were expressed as Mean±SEM (n = 10) *p<0.05.
**p< 0.01; ***p<0.001 versus normal saline treated control group,
the data was analyzed using One Way ANOVA followed by Tukeys multiple
comparison post hoc tests |
Table 2: |
Effect of aqueous bulb extract of Crinum glaucum (CG)
in Strychnine (STR)-, Pentylenetetrazole (PTZ)-and N-methyl-D-aspartic acid
(NMDA) induced seizures in mice |
 |
NC: No convulsion, the data were expressed as mean±SEM
(n = 7). *p<0.05, **p<0.01, ***p<0.001 versus normal saline treated
control group, ap<0.05 versus CG 400 mg kg-1 treated
group, the data was analyzed using One Way ANOVA followed by Tukeys
multiple comparison Post hoc tests |
Phenobarbitone (40 mg kg-1) also significantly (p<0.001) increased
the onset of tonic from 29.20±0.40 s in saline treated control to 129.60±13.00
s.
Pentylenetetrazole induced seizures: PTZ (90 mg kg-1, i.p.)
elicited tonic convulsion in 100% of the animals used in normal saline treated
control. CG (800 and 1200 mg kg-1, p.o.) dose dependently delayed
the onset of PTZ (90 mg kg-1, i.p.)-induced clonic convulsion significantly
(p<0.05, 0.001), respectively (Table 2).
The extract at 800 mg kg-1 increased the time of onset of clonic
seizure from 53.60±1.21 s in saline treated control to 67.00±1.05
sec and provided 20% protection while the extract at 1200 mg kg-1
protected 20% of mice against seizure and increased the time of onset of clonic
seizure from 53.60±1.21 sec in saline treated control to 82.20±5.77
sec. Phenobarbitone (40 mg kg-1 i.p.) profoundly antagonized the
clonic seizures induced by PTZ and also protected all the mice against seizures
(Table 2).
NMDA induced seizures: NMDA-induced seizures in rodents have previously
been proposed as a model of refractory seizures and are significantly suppressed
by NMDA receptor antagonists (Velisek, 2006). NMDA (100
mg kg-1, i.p.) elicited turning behaviour in 100% of normal saline
treated control mice with an onset of 121±0.55 sec to tonic seizures.
CG (800 and 1200 mg kg-1, p.o.) did not affect the incidence of NMDA
(100 mg kg-1, i.p.) induced turning behaviour but significantly (p<0.05)
delayed the onset of turning from 121.00±0.55 sec in control to 158.00±8.36
and 189.60±10.11, respectively (Table 2). However,
oral administration of phenobarbitone failed to increase the onset of turning
behaviour.
Possible involvement of GABAergic, serotonergic and nitric oxide pathways
in the anticonvulsant activity of Crinum glaucum: Intraperitoneal
pretreatment with flumazenil (3 mg kg-1) reversed the protective
effect of Crinum glaucum. Pretreatment with cyproheptadine (3 mg kg-1)
followed by CG 1200 mg kg-1 showed significant (p< 0.05) reduction
in the latency to seizure in comparison to CG (1200 mg kg-1) only
treated group. Nitric oxide synthase inhibitor (L-NNA) significantly (p<0.01)
reduced the latency to convulsion when compared with the normal saline treated
group. However, nitric oxide precursor co-treatment (L-arginine (500 mg kg-1)
+CG 1200 mg kg-1) produced a significant (p< 0.001) increase in
the time of onset of clonic seizure in comparison to L-NNA + CG (1200 mg kg-1)
co-treated and 40% protection was observed (Table 3).
Table 3: |
Effect of co treatment with flumazenil, cyproheptadine, L-arginine
and L-NG-Nitroarginine and aqueous bulb extract of Crinum glaucum
(CG) in picrotoxin (PCT)-induced seizures in mice |
 |
The data were expressed as mean±SEM (n = 10) *p<0.05;
**p<0.01; ***p<0.001 versus normal saline treated control group, +p<0.05;
++p<0.01 versus C. glaucum 1200 mg kg-1 treated group;
ap< 0.01, bp<0.001 versus L-NG- Nitroarginine+C.
glaucum 1200 mg kg-1 treated group, the data was analyzed
using One Way ANOVA followed by Tukeys multiple comparison post
hoc tests |
Table 4: |
Effect of aqueous bulb extract of Crinum glaucum (CG) on
potentiation of hexobarbitone sleeping time |
 |
The data were expressed as Mean±S.E.M (n = 7). ***p<
0.001 versus normal saline treated control group, the data was analyzed
using One Way ANOVA followed by Tukeys multiple comparison post
hoc tests |
Table 5: |
Effect of Crinum glaucum on elevated plus maze test |
 |
The data were expressed as Mean±SEM (n = 7), **p<0.01,
***p< 0.001 versus normal saline treated control group, #p<
0.001 compared to diazepam 1.5 mg kg-1, ap< 0.001
compared to CG 100 mg kg-1, the data was analyzed using One Way
ANOVA followed by Tukeys multiple comparison post hoc tests |
Effect of aqueous bulb extract of Crinum glaucum potentiation of
hexobarbitone-induced sleeping time: The normal saline treated group (control
group) gave an onset of sleep of 3.92±0.10 min and duration of 39.79±0.72
min when hexobarbitone was administered (Table 4). The aqueous
extract of C. glaucum (200-1200 mg kg-1) significantly (p<
0.001) reduced the latency to sleep while it also significantly (p<0.001)
prolonged the duration of sleep induced by hexobarbitone. The peak hypnotic
effect was obtained at 400 mg kg-1 CG treated where the onset of
sleep was significantly (p<0.001) reduced from 3.92±0.10 min in saline
treated to 1.52±0.01 min while the duration of sleep was significantly
(p<0.001) increased from 39.79±0.72 min in saline treated to 77.50±0.81
min. similarly, oral administration of diazepam produced significant (p<0.01)
reduction in the onset of sleep (2.40±0.24) and prolonged the duration
of sleep (82.00±7.19 min) induced by hexobarbitone in comparison to saline
control group. The hypnotic effect of diazepam was comparable to that of CG
(400 mg kg-1) (Table 4).
Effect of aqueous bulb extract of Crinum glaucum on elevated plus
maze: The normal saline treated animals (control group) showed that 23.40±2.32
s was spent in the open arms (Table 5). The aqueous extract
Crinum glaucum produced significant (p<0.01-0.001) increase in the
time spent in the open arms compared to control. Diazepam produced significant
(p<0.001) increase in the time spent in the open arms. The extract peak anxiolytic
effect (highest time spent in open arms) was produced at 100 mg kg-1
(124.00±1.18 s) and it is significantly (p<0.05) higher than that
produced by diazepam (84.4±2.84 s) (Table 5).
DISCUSSION
Most of conventional antiepileptic drugs are associated with many side effects
such as neurotoxic effects, cognitive deficits and teratogenic effects which
decrease their clinical utility (Trimble, 1987; Yerby,
1988; Meador et al., 1990). Recently, the
search for novel pharmacotherapy from medicinal plants for neurological and
psychiatric diseases has progressed significantly owing to their less side effects
and better tolerability (Zhang, 2004). In the present
study the anticonvulsant, anxiolytic and hypnotic activities of bulb extract
of C. glaucum have been studied. The results obtained in this study demonstrate
that the extract dose dependently increased the onset of convulsion induced
by picrotoxin, isoniazid, strychnine, pentylenetetrazole and NMDA as well as
significant prolongation of sleeping time and time spent in open arms in hexobarbitone
induced hypnosis and elevated plus maze tests, respectively.
Picrotoxin exerts its convulsant effect by blocking GABAA receptor-linked
chloride ion channel which, normally opens to allow increased chloride ion conductance
into the brain cells following activation of GABAA receptors by GABA
(Nicoll, 2001; Rang et al.,
2003). Phenobarbitone is a standard antiepileptic drug that has been shown
to exert its effect by enhancing GABA-mediated inhibition in the brain (Porter
and Meldrum, 2001). In picrotoxin-induced seizures, the plant extract at
doses 400 and 1200 mg kg-1 significantly delayed the onset of picrotoxin
elicited clonic seizures in mice. The extract at 800 and 1200 mg kg-1
protected 40% of the mice while 400 mg kg-1 protected 20% of the
mice. Phenobarbitone significantly delayed the onset of clonic seizures while
also protecting 100% of the mice. The plant extract at 1200 mg kg-1
produced the highest onset of seizures and also protected 40% of the animals
from seizures suggesting that the extract exerts its effect possibly by the
enhancement of GABA neurotransmission to attenuate picrotoxin induced convulsion.
Isoniazid exerts its convulsive effect by inhibiting GABA synthesis (Costa
et al., 1975). It is a potent monoamine oxidase (MAO) inhibitor and
a glutamic acid decarboxylase (GAD) inhibitor (enzyme involved in GABA synthesis)
thus increases the brain monoamine content and inhibited GABA synthesis respectively
thereby leading to CNS excitation and convulsions (Wood
and Peesker, 1973; Marcus and Coulsto, 1985). Isoniazid
induced seizures was carried out to further confirm the GABA enhancing activity
of the plant extract. The extract (400-1200 mg kg-1) when compared
to control treated produced significant increase in the time of onset of clonic
seizures, this shows dose-dependent increase in the anticonvulsant activity.
Phenobarbitone did not affect the incidence of seizures or death but significantly
delayed the onset of seizures.
Strychnine is a selective competitive antagonist that blocks the inhibitory
effect of glycine at all glycine receptors (Rajendra
et al., 1997; Parmar and Prakash, 2006). In strychnine
induced seizures, the plant extract did not protect the animals from seizure
or death but increased the seizure onset significantly in a dose dependent manner.
Phenobarbitone did not affect the incidence of seizures nor prevent death but
delayed the onset of seizures significantly when compared to control (normal
saline) group. The peak increase in onset of seizure by CG was obtained at 1200
mg kg-1. This shows that the extract may have minimal glycine receptor
antagonism.
PTZ mostly exerts its action by inhibiting the t-butyl-bicyclo-phosphorothionate
/ picrotoxin site of the GABAA receptor (Velisek,
2006) and thereby preventing chloride ion conductance into the brain cells.
There is also the involvement of Na+/Ca2+ exchanger (NCX)
in PTZ induced convulsion (Salto et al., 2009).
In PTZ induced seizures, phenobarbitone completely inhibited the incidence of
seizures. The plant extract however did not protect the animals from seizures,
but increased the seizure onset significantly with 20% protection at 800 and
1200 mg kg-1. This result shows that the effect of phenobarbitone
and the extract are not comparable, but the effect of the plant extract in this
model cannot be totally ignored as they still lowered onset of convulsion and
protected 20% of the animals. It can then be said that the extract is not very
effective in preventing PTZ induced seizures and this could be due to the additional
mechanisms by which PTZ acts to induce convulsion other than inhibiting GABAA
receptors.
NMDA is an agonist that produces effects similar to glutamic acid at the NMDA
receptors and exerts its convulsant effect by activating the receptors to enhance
glutaminergic neurotransmission (Watkins and Evans, 1981;
Chapman and Meldrum, 1993). NMDA-induced seizures in
rodents have previously been proposed as a model of refractory seizures and
are significantly suppressed by NMDA receptor antagonists (Velisek,
2006). In NMDA induced seizures, the plant extract did not protect the animals
from seizures and death but increased the seizure onset significantly (p<0.05;
0.001) in a dose dependent manner (at doses 800 and 1200 mg kg-1),
respectively. The plant extract at 1200 mg kg-1 produced a delayed
onset and shorter duration of seizures when compared to phenobarbitone and so
had a better anticonvulsant effect in this model, showing that this is the most
effective dose. This shows that phenobarbitone does not act by blocking glutamate
transmission and that the extract also possesses minimal anti-glutaminergic
activity compared to phenobarbitone.
The probable mechanism of anticonvulsant effect of bulb extract of C. glaucum
was investigated in picrotoxin induced seizure using the most effective
dose of the extract (1200 mg kg-1). To confirm GABA or effect at
allosteric benzodiazepine receptor on GABA. Animals were pretreated with flumazenil
(a benzodiazepine receptor antagonist), Flumazenil had no significant anticonvulsant
activity when it was administered alone. Phenobarbitone and flumazenil co-treated
group gave no significant reduction in its onset of convulsion when compared
to phenobarbitone treated group only and also gave 100% protection, implying
that flumazenil has relatively no effect on the action of phenobarbitone. However,
flumazenil pretreatment reversed the anticonvulsant effect of the bulb extract
of C. glaucum. This further confirm that C. glaucum may be acting
as an agonist of the GABAA-benzodiazepine receptor complex.
Despite the similarity in the seizure phenotype induced by PTZ and picrotoxin,
marked difference between their pharmacological profiles have been observed,
like carbamazepine, a clinically used anticonvulsant is effective against seizures
induced by MES and picrotoxin but not in seizures induced by PTZ (White,
1998). Carbamazepine has also been reported to increase serotonergic neurotransmission
as one of its proposed anticonvulsant mechanism (Dailey
et al., 1995; Bagdy et al., 2007).
In our studies cyproheptadine (5-HT2 receptor antagonist) pretreatment
failed to reversed the anticonvulsant activity of C. glaucum extract
ruling out the involvement of serotonergic neurotransmission in its anticonvulsant
activity.
The possible involvement of NO in the anticonvulsant activity of C. glaucum
was investigated by administration of NO precursor (L-arginine 500 mg kg-1)
and NOS inhibitor (L-NNA 10 mg kg-1).
It has been shown that 30 and 60 min pretreatment of 1000 mg kg-1
and not 500 mg kg-1 of L-arginine inhibited convulsions induced by
picrotoxin, while a Nitric Oxide Synthase (NOS) inhibitor, N-nitro-L-arginine
methyl ester (L-NAME) increased convulsant action of picrotoxin (Paul
and Subramanian, 2002). The concentrations of nitric oxide (NO) and Gamma
Aminobutyric Acid (GABA) were increased in the brain 30 and 60 min after administration
of 1000 mg kg-1 and not 500 mg kg-1 of L-arginine. However,
L-NAME decreased brain GABA concentration and increased the convulsant action
of picrotoxin. Further, L-NAME pretreatment prevented L-arginine (1000 mg kg-1)
from producing anticonvulsant and NO and GABA increasing effects (Paul
and Subramanian, 2002). In this study, L-arginine 500 mg kg-1
alone produced seizures in all mice used, with 100% mortality. However, when
L-arginine when co administered with the extract (1200 mg kg-1),
it produced a significant increase in onset of seizures and 40% protection when
compared with extract only treated group. In addition, L-NG-Nitroarginine
pretreatment reduced the antiseizure activity of the extract. These results
support the suggestions of previous investigators that NO modulates the concentration
of GABA in the brain (Paul and Jayakumar, 2000). NO
seems to increase GABA concentration by decreasing GABA transaminase (GABA-T)
activity in the brain because a decreased concentration of GABA by an NO decreasing
dose of L-NAME coincided with an increased activity of GABA-T in the brain (Paul
and Jayakumar, 2000). These observations and the ability of L-NNA in the
present study to prevent C.glaucum from inhibiting seizure, provide further
support to the suggestion that NO functions as a modulator of GABA concentration
in the brain. Further, NO has been found to activate release of GABA from cerebral
cortex (Kuriyama and Ohkuma, 1995), striatum (Lonart
et al., 1992) and hippocampus (Segovia and
Mora, 1998). Conversely, inhibitors of NO synthesis have decreased GABA
release in the cerebral cortex (Montague et al.,
1994). These results by NO Bie and Zhao (2001),
strongly support the suggestion that a functional interaction occurs between
NO and GABA in the brain. This shows that the extract probably acts by increasing
the concentration of nitric oxide and GABA concentration in the brain of mice.
The aqueous extract produced a significant (p<0.001) reduction in the onset
of sleep induced by hexobarbitone at 200-1200 mg kg-1 and significant
(p<0.001) prolongation of sleep at doses 400 and 1200 mg kg-1.
The prolongation of sleep observed at 400 mg kg-1 is comparable to
that produced by diazepam 3 mg kg-1 and therefore when compared to
each other, there was no significant difference in the duration of sleep observed
in both treatments. Prolongation of hexobarbitone sleeping time indicates a
central nervous system depressant activity of the extract (Mujumdar
et al., 2000). It also indicates that the extract is an enzyme inhibitor
as possibly increased the action of hexobarbitone by preventing its metabolism.
Furthermore, this work demonstrated that the administration of different doses
of CG in mice was able to induce anxiolytic effect. The elevated plus maze is
considered to be an etiologically valid animal model of anxiety because it uses
natural stimuli (fear of a novel open space and fear of balancing on a relatively
narrow, raised platform) that can induce anxiety in humans (Dawson
and Tricklebank, 1995). An anxiolytic agent increases the frequency of entries
into the open arms and increases the time spent in open arms of the EPM. In
the present study, oral administration of C.glaucum induced an anxiolytic-like
effect in mice, since it increased the number of entries and the time spent
on open arms and decreased the time spent in closed arms in the EPM test. In
agreement with previously published reports, diazepam increased the duration
of time spent on open arms and the number of entries on open arms (Ishola
et al., 2012).
The aqueous extract (100-1200 mg kg-1) significantly increased time
spent in open arms of the elevated plus maze but no statistical difference in
the number of entries (result not shown). The anxiolytic effect peaked at 100
mg kg-1 which was comparable to diazepam.
We have no adequate explanation for the lack of dose dependence in this assay.
Further studies to investigate the effect of Crinum glaucum at different
intervals of time might disclose a dose-dependent effect.
The result of the acute oral toxicity showed that the extract possesses wide
margin of safety which is in agreement with previous study of Okpo
et al. (2001).
The phytochemical constituents of the plant include phenols, flavonoids, glycosides
and alkaloids. One or more of these substances may be involved in the anticonvulsant
activity of the extract.
CONCLUSION
In conclusion, the present study provides scientific evidence for the use of
bulb of Crinum glaucum in treatment of epileptic and anxiety disorders
by Southwestern Nigerians. Crinum glaucum exerts its anticonvulsant and
anxiolytic effects by increasing the concentration, release and the activity
of GABA which is a well-documented inhibitory neurotransmitter in the brain
possessing an anticonvulsant and anxiolytic properties.
ACKNOWLEDGMENTS
The authors are grateful to Mr. Micah Chijioke of the Department of Pharmacology,
College of Medicine, University of Lagos, Lagos, Nigeria, for technical assistance
rendered in the course of this research work.
|
REFERENCES |
1: Adeyemi, O.O., O.K. Yemitan and O.A. Olayemi, 2007. Sedative and anticonvulsant activities of the aqueous root extract Sanseviera liberica Gerome and Labroy (Agavaceae). J. Ethnopharmacol., 113: 111-114. CrossRef |
2: Bagdy, G., V. Kecskemeti, P. Riba and R. Jakus, 2007. Serotonin and epilepsy. J. Neurochem., 100: 857-873. CrossRef |
3: Bernasconi, R., M. Klein, P. Martin, P. Christen, T. Hafne, C. Portet and M. Schmutz, 1988. Gamma-Vinyl GABA: Comparison of neurochemical and anticonvulsant effects in mice. J. Neural Trans., 72: 213-233. CrossRef | Direct Link |
4: Bie, B.H. and Z.Q. Zhao, 2001. Nitric oxide inhibits GABA-evoked current in dorsal root ganglion neuron via PKG-dependent pathway. Brain Res. Bull., 55: 335-339. CrossRef |
5: Burkill, H.M., 1985. The Useful Plants of West Tropical Africa. 2nd Edn., Vol. 2, Royal Botanic Gardens, Kew, London, Pages: 960.
6: Chapman, A.G. and B.S. Meldrum, 1993. Excitatory amino acid antagonists and epilepsy. Biochem. Soc. Trans., 21: 106-110. PubMed |
7: Costa, E., A. Guidotti and C.C. Mao, 1975. Evidence for involvement of GABA in the action of benzodiazepines: studies on rat cerebellum. Adv. Biochem. Psychopharmacol., 14: 113-130. PubMed | Direct Link |
8: Dailey, J.W., Q.S. Yan, L.E. Adams, J.R. Ryu, K.H. Ko, P.K. Mishra and P.C. Jobe, 1995. Neurochemical correlates of antiepileptic drugs in the Genetically Epilepsy-Prone Rat (GEPR). Life Sci., 58: 259-266. CrossRef |
9: Dawson, G.R. and M.D. Tricklebank, 1995. Use of the elevated plus maze in the search for novel anxiolytic agents. Trends Pharmacol. Sci., 16: 33-36. CrossRef |
10: Duri, Z.J., J.P. Scovill and J.W. Huggins, 1994. Activity of a methanolic extract of Zimbabwean Crinum macowanii against exotic RNA viruses in vitro. Phytother. Res., 8: 121-122. CrossRef |
11: Gbile, Z.O., 1984. Vernacular Names of Nigerian Plants (Yoruba). Forestry Research Institute of Nigeria, Ibadan, Nigeria.
12: Gupta, G., I. Kazmi, M. Afzal, M. Rahman and S. Saleem et al., 2012. Sedative, antiepileptic and antipsychotic effects of Viscum album L. (Loranthaceae) in mice and rats. J. Ethnopharmacol., 141: 810-816. CrossRef | Direct Link |
13: Houghton, P.J., J.M. Agbedahunsi and A. Adegbulugbe, 2004. Choline esterase inhibitory properties of alkaloids from two Nigerian Crinum species. Phytochemistry, 65: 2893-2896. CrossRef |
14: Ishola, I.O., M. Chatterjee, S. Tota, N. Tadigopulla, O.O. Adeyemi, G. Palit and R. Shukla, 2012. Antidepressant and anxiolytic effects of amentoflavone isolated from Cnestis ferruginea in mice. Pharmacol. Biochem. Behav., 103: 322-331. CrossRef | Direct Link |
15: Kokwako, J.O., 1976. Medicinal Plants of East Africa. East African Literature Bureau Kampala, Nairobi pp: 62.
16: Kuriyama, K. and S. Ohkuma, 1995. Role of nitric oxide in central synaptic transmission: Effects on neurotransmitter release. Jpn. J. Pharmacol., 69: 1-8. CrossRef | PubMed | Direct Link |
17: Lonart, G., J. Wang and K.M. Johnson, 1992. Nitric oxide induces neurotransmitter release from hippocampal slices. Eur. J. Pharmacol., 220: 271-272. CrossRef |
18: Marcus, R. and A.M. Coulsto, 1985. Water Soluble Vitamins. In: The Pharmacological Basis of Therapeutics, Gilman, A.G., L.S. Goodman, T.W. Rall and F. Murad (Eds.). 7th Edn. Macmillan Publishing Co., New York, USA., pp: 1551-1572.
19: Meador, K.J., D.W. Loring, K. Huh, B.B. Gallagher and D.W. King, 1990. Comparative cognitive effects of anticonvulsants. Neurology, 40: 391-394. CrossRef | Direct Link |
20: Montague, P.R., C.D. Gancayco, M.J. Winn, R.B. Marchase and M.J. Friedlander, 1994. Role of NO production in NMDA receptor-mediated neurotransmitter release in cerebral cortex. Science, 263: 973-977. CrossRef | PubMed | Direct Link |
21: Mujumdar, A.M., D.G. Naik, R.J. Waghole, D.K. Kulkarni and M.S. Kumbhojkar, 2000. Pharmacological studies on Sterculia foetida leaves. Pharma. Biol., 38: 13-17. PubMed |
22: Nicoll, R.A., 2001. Introduction to Pharmacology of CNS Drugs. In: Basic and Clinical Pharmacology, Katzung, B.G. (Ed.). 8th Edn. Lange Medical Books/McGraw-Hill, New York, USA., pp: 351-363.
23: Nogueira, E. and V.S. Vassilieff, 2000. Hypnotic, anticonvulsant and muscle relaxant effects of Rubus brasiliensis. Involvement of GABAA-system. J. Ethanopharmacol., 70: 275-280. CrossRef | PubMed | Direct Link |
24: Okpo, S.O. and O.O. Adeyemi, 2002. The anti-allergic effects of Crinum glaucum aqueous extract. Phytomedicine, 9: 438-441. CrossRef |
25: Okpo, S.O. and O.O. Adeyemi, 1998. Effects of Crinum glaucum aqueous extract on intestinal smooth muscle activity. Phytother. Res., 12: 413-416. CrossRef |
26: Okpo, S.O., F. Fatokun and O.O. Adeyemi, 2001. Analgesic and anti-inflammatory activity of Crinum glaucum aqueous extract. J. Ethnopharmacol., 78: 207-211. CrossRef | PubMed | Direct Link |
27: Oliver, B., 1959. Medicinal Plants in Nigeria. Nigerian College of Arts, Science and Technology, Ibadan, Nigeria, pp: 98.
28: Parmar, N.S. and S. Prakash, 2006. Screening Methods in Pharmacology. Narosa Publishing House, New Delhi.
29: Paul, V. and A.R. Jayakumar, 2000. A role of nitric oxide as an inhibitor of γ-aminobutyric acid transaminase in rat brain. Brain Res. Bull., 51: 43-46. CrossRef |
30: Paul, V. and E.H. Subramanian, 2002. Evidence for an involvement of nitric oxide and gamma aminobutyric acid in the anticonvulsant action of L-arginine on picrotoxin-induced convulsions in rats. Pharmacol. Bioch. Behav., 72: 515-519. CrossRef | Direct Link |
31: Pellow, S., P. Chopin, S.E. File and M. Briley, 1985. Validation of open: Closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods, 14: 149-167. CrossRef | Direct Link |
32: Perazzo, F.F., J.C.T. Carvalho, J.E. Carvalho and V.L.G. Rehder, 2003. Central properties of the essential oil and the crude ethanol extract from aerial parts of Artemisia annua. J. Pharmacol. Res., 48: 497-502. CrossRef |
33: Porter, R.J. and B.S. Meldrum, 2001. Antiseizure Drugs. In: Basic and Clinical Pharmacology, Katzung B.G. (Ed.). 8th Edn. Lange Medical Books/McGraw-Hill, New York, USA., pp: 585-587.
34: Rajendra, S., J.W. Lynch and P.R. Schofield, 1997. The glycine receptor. Pharmacol. Therapeut., 73: 121-146. CrossRef | Direct Link |
35: Rang, H.P., M.M. Dale, J.M. Ritter and P.K. Moore, 2003. Pharmacology. 5th Edn., Churchill Livingstone, Edinburg, UK., pp: 585-587.
36: Salto, R., E. Kaneko, Y. Tanaka, K. Honda and T. Matsuda et al., 2009. Involvement of Na+/Ca2+ exchanger in pentylenetetrazol-induced convulsion by the use of Na+/Ca2+ exchanger knockout mice. Biol. Pharm. Bull., 32: 1928-1930. CrossRef |
37: Segovia, G. and F. Mora, 1998. Role of nitric oxide in modulating the release of dopamine, glutamate and GABA in striatum of the freely moving rat. Brain Res. Bull., 45: 275-280. CrossRef |
38: Trimble, M.R., 1987. Anticonvulsant drugs and cognitive function: A review of the literature. Epilepsia, 28: S37-S45. CrossRef |
39: Velisek, L., 2006. Models of Chemically Induced Acute Seizures. In: Models of Seizures and Epilepsy, Pitkanen, A., P.A. Schwartzkroin and L.M. Solomon (Eds.). Elsevier Academic Press, San Diego, California, USA., pp: 127-152.
40: Vogel, H.G. and W.H. Vogel, 1997. Potentiation of Hexobarbital Sleeping Time. In: Drug Discovery and Evaluation, Vogel, H.G. and W.H. Vogel (Eds.). Springer-Verlag Berlin Heidelberg, New York, pp: 267-268.
41: Watkins, J.C. and R.H. Evans, 1981. Excitatory amino acid transmitters. Ann. Rev. Pharmacol. Toxicol., 21: 165-204. CrossRef | Direct Link |
42: White, H.S., 1998. Chemoconvulsants. In: Neuropharmacology Methods in Epilepsy Research, Peterson, S.L. and T.E. Albertson (Eds.). CRC Press, New York, USA., ISBN-13: 978-0849333620, pp: 27-40.
43: Wood, J.D. and S.J. Peesker, 1973. The role of gaba metabolism in the convulsant and anticonvulsant actions of aminooxyacetic acid. J. Neurochem., 20: 379-387. CrossRef |
44: Yerby, M.S., 1988. Teratogenicity of Antiepileptic Drugs. In: Recent Advances in Epilepsy, Pedley, T.A. and B.S. Meldrum (Eds.). Churchill Livingstone, New York, USA., pp: 93-107.
45: Zhang, Z.J., 2004. Therapeutic effects of herbal extracts and constituents in animal models of psychiatric disorders. Life Sci., 75: 1659-1699. CrossRef | Direct Link |
46: NIH, 1985. Guide for the use of laboratory animals DHHS, PHS. NIH Publication No. 85-23.
47: Michael, A.R., 2006. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res., 69: 273-294. CrossRef | Direct Link |
|
|
|
 |